A new £6.2m investment will expand the National Centre for Neurotechnology and Neurorestoration (NCNN), strengthening the UK’s ability to evaluate and translate emerging neurotechnologies safely and effectively.
We're investing £3.1m, matched by Newcastle upon Tyne Hospitals NHS Foundation Trust. Together with Newcastle University, the partners will scale NCNN’s specialist workforce, facilities and national partnerships.
Established in 2025, NCNN is the UK’s first centre dedicated to technologies that interact with the brain and nervous system. Based in Newcastle, it brings together clinical care, research, innovation and education to help determine how promising neurotechnologies can work in practice and, where appropriate, progress towards wider use.
Rather than supporting a single device or study, the investment will build a nationally connected, NHS-embedded capability. NCNN will bring together expertise in clinical-study design, regulatory strategy, governance, evidence generation, training and implementation, and will coordinate a wider network of clinical and research partners across the UK.
The centre will support innovators, researchers and NHS organisations—including our Creator teams—working to develop new neurotechnologies.
“There is an extraordinary amount of innovation in neurotechnology right now. The hard part is not simply inventing a new device — it is working out how to get it to the people who need it most. NCNN gives us a real-world place to do that. ARIA’s investment will help build the clinical and regulatory capability needed to translate the most promising neurotechnologies, both within our programmes and across the broader ecosystem, into real-world impact.”
Jacques CarolanProgramme Director